International Society for Stem Cell Research– tag –
-
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons... -
Organoid Research Showcased at ISSCR 2026: iPSC and Adult Stem Cell-Derived Systems Drive Breakthroughs in Organogenesis and Disease Modeling
International Society for Stem Cell Research (ISSCR) International Overview The ISSCR 2026 annual meeting highlighted the latest innovations and technical advancements in organoid technology, particularly emphasizing iPSC and adult stem ... -
ISSCR to Host iPSC 20th Anniversary Symposium in Kyoto, Japan in October 2026, Celebrating Two Decades of Breakthrough Science
International Society for Stem Cell Research (ISSCR) Japan Overview The International Society for Stem Cell Research (ISSCR) announced a symposium in Kyoto, Japan, in October 2026, commemorating the 20th anniversary of iPSC discovery. Th... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Phase 1/2a Trial of Autologous iPSC-Derived Dopaminergic Progenitors for Parkinson’s Shows Positive 12-Month Interim Results in 8 Patients, Demonstrating Favorable Safety and Functional Improvement
International Society for Stem Cell Research USA Overview Interim clinical results from the first Phase 1/2a trial of autologous iPSC-derived dopaminergic progenitor cells for Parkinson's Disease were presented at ISSCR 2026, showing fav... -
Landmark Phase 1b/2a REGEN4HD Trial for Huntington’s Disease with Pluripotent Stem Cell-Derived Neural Stem Cells Unveiled at ISSCR 2026
International Society for Stem Cell Research International Overview The first clinical trial (Phase 1b/2a REGEN4HD study) of pluripotent stem cell-derived neural stem cells for Huntington's Disease was highlighted at the ISSCR 2026 annua... -
Fate Therapeutics to Announce Preliminary Clinical Data for iPSC-Derived CAR T-Cell FT819 for Systemic Sclerosis at ISSCR 2026
GlobeNewswire USA Overview Fate Therapeutics announced it will present preliminary clinical data for its iPSC-derived 'off-the-shelf' CAR T-cell candidate FT819 for systemic sclerosis (SSc) at the International Society for Stem Cell Rese... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa... -
First-in-Human Pluripotent Stem Cell-Derived Neural Stem Cell Therapy for Huntington’s Disease (Regen4HD) Reports Phase 1b/2a Updates at ISSCR 2026
PharmaTimes USA Overview Updates from the first-in-human Phase 1b/2a clinical trial of Regen4HD, a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease, were presented at the ISSCR 2026 Annual Meeting. This lan...
1